| gap-pubmed-20260410- | What mechanisms cause α-synuclein seeding activity to decrease with longer PD di | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What is the therapeutic window and dosing strategy for urolithin A in preventing | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does TGM2 mechanistically regulate ER-mitochondria contact sites in neuronal | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines when cells use the ALIX-ESCRT-III pathway versus the canonical E | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does the ALIX-ESCRT-III pathway specifically recognize and sort tetraspanins | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines individual variability in NF-L trajectories in Down syndrome? | open | 0.72 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does NF-L relate to specific AD neuropathological changes in Down syndrome? | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms drive the steep increase in NF-L after age 40 in Down syndrome? | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does baseline cardiovascular disease double neuropathy risk independent of c | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms link cardiovascular risk factors to diabetic neuropathy developm | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does clomipramine simultaneously target genomic instability and neuroinflamm | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Will clomipramine's efficacy translate from Drosophila to mammalian SOD1-ALS mod | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms underlie clomipramine's therapeutic effects in SOD1-AL | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does peripheral colonic inflammation specifically trigger blood-brain barrie | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Why does GPR109A blockade only partially abolish niacin's neuroprotective effect | open | 0.84 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Do other high-confidence autism genes beyond the five tested also disrupt enteri | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodevelopment |
| gap-pubmed-20260410- | How do serotonin signaling modulators rescue gut dysmotility caused by DYRK1A pe | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neuropharmacology |
| gap-pubmed-20260410- | What molecular mechanisms link autism gene variants to disrupted enteric neuron | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodevelopment |
| gap-pubmed-20260410- | What mechanisms allow neuroinflammation to directly drive synaptic loss independ | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do TNF-α-lowering compounds achieve sufficient brain penetration for therape | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What is the optimal therapeutic time window to preserve beneficial neuroinflamma | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What molecular mechanisms link aggrephagy marker accumulation to disease severit | resolved | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why is aggrephagy specifically hyperactivated in MYOT-mutated patients compared | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does cholesterol accumulation specifically impair osteoblast proliferation a | open | 0.56 | 0.00 | 2026-04-10 | 0 | | bone-metabolism |
| gap-pubmed-20260410- | How does the GLP-1R/ABCA1 axis mechanistically link cholesterol metabolism to os | open | 0.64 | 0.00 | 2026-04-10 | 0 | | bone-metabolism |
| gap-pubmed-20260410- | What mechanisms explain DMF's increase in hemoglobin F production in sickle cell | open | 0.85 | 0.00 | 2026-04-10 | 0 | | hematopoiesis |
| gap-pubmed-20260410- | How does DMF improve sickle cell pathology without reducing hemolysis or plasma | open | 0.80 | 0.00 | 2026-04-10 | 0 | | oxidative-stress-biology |
| gap-pubmed-20260410- | Why do some homozygous APOE ε4 carriers not develop AD despite maximum genetic r | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do complex APOE ε2/ε4 interactions with other polymorphisms determine AD res | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms underlie race/ethnicity-specific APOE haplotype effect | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do acetylation subtypes show differential immune cell infiltration patterns | open | 0.74 | 0.00 | 2026-04-10 | 0 | | neuroimmunology |
| gap-pubmed-20260410- | How does warm-needle acupuncture mechanistically trigger systemic acetylation ch | open | 0.73 | 0.00 | 2026-04-10 | 0 | | pain-neuroscience |
| gap-pubmed-20260410- | How does transepithelial potential interact with PEDF to regulate retinal aging | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms control PEDF secretion from RPE cells in health and disease? | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Do these circadian interventions extend lifespan and reverse aging biomarkers in | open | 0.78 | 0.00 | 2026-04-10 | 0 | | aging-neurobiology |
| gap-pubmed-20260410- | Why does PVN circadian enhancement specifically reverse epigenetic aging markers | open | 0.82 | 0.00 | 2026-04-10 | 0 | | aging-neurobiology |
| gap-pubmed-20260410- | How does 3'-deoxyadenosine mechanistically enhance RUVBL2-dependent circadian tr | open | 0.80 | 0.00 | 2026-04-10 | 0 | | circadian-neurobiology |
| gap-pubmed-20260410- | What causes the stalled phagocytosis phenotype in tau-mutant microglia and how d | resolved | 0.81 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How do secretory factors from mutant tau microglia specifically reduce synaptic | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | What molecular mechanisms link MAPT IVS10+16 mutation to disrupted TREM2/TYROBP | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How do regional brain glucose utilization and perfusion changes in LOAD1.Plcg2 m | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms link Plcg2 M28L variant to transcriptomic signatures r | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does the Plcg2 M28L variant specifically sensitize mice to HFD-induced neuro | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What determines whether exported JDPs enhance proteostasis vs. confer pathologic | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do classical vs. unconventional secretory pathways differentially regulate J | open | 0.81 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms govern selective vs. non-selective substrate recogniti | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does butyrate's HDAC inhibition specifically contribute to its neuroprotecti | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which butyrate promotes recovery f | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do glycerolipid metabolism and viral myocarditis pathways contribute to Lewy | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms underlie the differential gene expression patterns bet | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |